Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Blog by Rima Shretta in the Centre for Tropical Medicine & Global Health (Nuffield Department of Medicine). As the COVID-19 pandemic continues its path to LMICs, its impact is likely to be even more devastating, potentially reversing recent gains made in the management of other communicable diseases. Of particular concern is the impact of the COVID-19 pandemic on malaria. COVID-19 has been slow to arrive and spread across Africa; nevertheless, there are many reasons to be concerned about malaria within the current context of the COVID-19 pandemic.

© Vanuata 2012

The virus that causes COVID-19, the SARS-CoV-2 virus, has rapidly spread across the world. On April 23, there were more than 2.7 million reported cases and 192,000 deaths globally. As the pandemic continues its path to low and low-middle income countries (LMICs), its impact is likely to be even more devastating, potentially reversing recent gains made in the management of other communicable diseases.

Of particular concern is the impact of the COVID-19 pandemic on malaria. There were an estimated 228 million cases of malaria and it caused 405,000 deaths in 2018. Sub-Saharan Africa accounted for approximately 93% of all cases and 94% of deaths, with more than two-thirds of deaths occurring among children below the age of five. The majority of people in malaria-endemic countries live in poverty and already face struggling health care systems and a scarcity of skilled health workers, both of which present additional barriers to accessing health care services. Nonetheless, progress in tackling malaria in the past 15 years has been notable. Both cases and deaths due to malaria have declined by about 50% since 2000. During this period, an additional eleven countries were declared malaria free by the World Health Organization (WHO). However, since 2014, due to extrinsic challenges (of which financing was one), progress has stalled. Without any risk mitigation strategies, disruption to malaria programs as a result of the spread of COVID-19 in malaria-endemic countries will set progress back even further.

Read the full blog on the Centre for Tropical Medicine & Global Health website

Similar stories

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

World’s largest clinical trial for COVID-19 treatments expands internationally

Clinical Trials Coronavirus COVID-19 General

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.

Reprogramming tumour cells using an antimalarial drug

General Research

Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.